Company Profiles

driven by the PitchBook Platform

Adrenergics

2015 FOUNDED
PRIVATE STATUS
Series A LATEST DEAL TYPE
$3M LATEST DEAL AMOUNT
$3M TOTAL AMOUNT RAISED
2 INVESTORS
Description

Developer of novel therapeutics designed to treat dilated cardiomyopathy (DCM). The company's therapeutics focuses on developing medicines that are expected to modulate disease progression leading to improved outcomes, enabling patients to overcome difficult-to-treat situations.

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Pharmaceuticals
Drug Discovery
Primary Office
San Diego, CA
United States
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Adrenergics’s full profile, request a free trial.

Adrenergics Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
1. Early Stage VC (Series A) 15-Jun-2015 $3M $3M 00.000 Completed Startup
To view this company’s complete deal history including valuation and funding request access »

Adrenergics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned
Series A 0,000,000 00.000000 00 00.00 00.00 00 00.00 000
To view this company’s complete Cap Table request access »

Adrenergics Investors (2)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
Avalon Ventures Venture Capital Minority 000 0000 000000 0
GSK Corporation Minority 000 0000 000000 0